Imactiv-3D


    
    
    


    




    












1 NOV 2019

APELYM3D start

Funded by the Occitanie region (France) and Imactiv-3D, this project aims to implement technological tools for 3D imaging of lymphatic vessels in adipose tissue and facilitate the characterization of the efficacy of therapeutic targets in preclinical models.

Funded by the Occitanie region (France) and Imactiv-3D, this project aims to implement technological tools for 3D imaging of lymphatic vessels in adipose tissue and facilitate the characterization of the efficacy of therapeutic targets in preclinical models.
26 AUG 2019

TERMIS in Nantes : 3D Bioprinting in Cancer Research

We presented our first light sheet imaging work on samples from bioprinting. As well as the potential for quantifying the diffusion of active ingredients, antibodies or immune cells in 3D biological models.

We presented our first light sheet imaging work on samples from bioprinting. As well as the potential for quantifying the diffusion of active ingredients, antibodies or immune cells in 3D biological models.
2 JUL 2019

AFSSI Lyon : Les rencontres de la recherche pré-clinique

Always fruitful meetings in a friendly atmosphere

Always fruitful meetings in a friendly atmosphere
24 JUN 2019

AIS Tours : 7th Antibody Industrial Symposium

Many thanks to all who were able to share with us during this event

Many thanks to all who were able to share with us during this event
21 MAY 2019

Meet2Win : Oncology Partening Convention

A great event in Bordeaux to build professional relationships

A great event in Bordeaux to build professional relationships
24 JAN 2019

Joint publication with an INSERM unit in Toulouse

Boosting γδ T cellmediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma, OncoImmunology, 8:3, 1554175, DOI: 10.1080/2162402X.2018.1554175

Boosting γδ T cellmediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma, OncoImmunology, 8:3, 1554175, DOI: 10.1080/2162402X.2018.1554175
31 DEC 2019

IMALC end

We have developed a quantitative analysis of the distribution and diffusion of ACM (Monoclonal antibody) on these 3D models of follicular lymphomas (MALC) based on 1) light sheet microscopy imaging of MALC after treatment with therapeutic ACMs and 2) the development of a custom methodology for efficient and automated image processing and analysis to quantitatively characterize the spatiotemporal biodistribution of ACMs within MALC. This project was based on the skills and expertise found in team N°9 of the CRCT (Toulouse Cancer Research Centre), on the imaging platform of the ITAV (Institut des Technologies Avancées du Vivant) and in the company IMACTIV3D.

We have developed a quantitative analysis of the distribution and diffusion of ACM (Monoclonal antibody) on these 3D models of follicular lymphomas (MALC) based on 1) light sheet microscopy imaging of MALC after treatment with therapeutic ACMs and 2) the development of a custom methodology for efficient and automated image processing and analysis to quantitatively characterize the spatiotemporal biodistribution of ACMs within MALC. This project was based on the skills and expertise found in team N°9 of the CRCT (Toulouse Cancer Research Centre), on the imaging platform of the ITAV (Institut des Technologies Avancées du Vivant) and in the company IMACTIV3D.
15 SEP 2019

Publication in virology

In vivo labelling of adenovirus DNA identifies chromatin anchoring and biphasic genome replication. J Virol 92:e00795-18. https://doi.org/10.1128/JVI.00795-18.

In vivo labelling of adenovirus DNA identifies chromatin anchoring and biphasic genome replication. J Virol 92:e00795-18. https://doi.org/10.1128/JVI.00795-18.
2 JUL 2018

AFSSI : Les rencontres annuelles de la recherche préclinique

Thank you for the many contacts and discussions during this networking in Marseille

Thank you for the many contacts and discussions during this networking in Marseille
27 JUN 2018

BioFab : Imactiv-3D sponsor of the 2nd workshop .

A great attendance at the workshop organized by our company in Bordeaux. http://biofab.canceropole-gso.org

A great attendance at the workshop organized by our company in Bordeaux. http://biofab.canceropole-gso.org
17 MAY 2018

Meet2Win : Oncology Meeting Convention

For our first participation in Meet2Win in Bordeaux, we are very happy with the meetings and feedback about our activity.

For our first participation in Meet2Win in Bordeaux, we are very happy with the meetings and feedback about our activity.
15 FEB 2019

First scientific publication

New procedure to visualize, analyze and quantify the pharmacological activity of drugs on 3D multicellular spheres grown in a physiological matrix. "Evaluation by quantitative image analysis of anticancer drug activity on multicellular spheroids grown in 3D matrix. " Oncol Lett 12: 4371-4376, 2016 DOI: 10.3892/ol.2016.5221

New procedure to visualize, analyze and quantify the pharmacological activity of drugs on 3D multicellular spheres grown in a physiological matrix. "Evaluation by quantitative image analysis of anticancer drug activity on multicellular spheroids grown in 3D matrix. " Oncol Lett 12: 4371-4376, 2016 DOI: 10.3892/ol.2016.5221
1 JAN 2019

IMLINFO (EFA281/16): Start of the European project

IMLINFO is a cross-border network of personalized immunotherapies against non-Hodgkin's lymphoma (NHL) involving 8 organizations located in Spain and France. Its main objective is to determine the efficacy of new immunotherapy treatments by creating a repository of non-Hodgkin's lymphoma (NHL) tumours associated with a three-dimensional (3D) culture platform.

IMLINFO is a cross-border network of personalized immunotherapies against non-Hodgkin's lymphoma (NHL) involving 8 organizations located in Spain and France. Its main objective is to determine the efficacy of new immunotherapy treatments by creating a repository of non-Hodgkin's lymphoma (NHL) tumours associated with a three-dimensional (3D) culture platform.
23 OCT 2017

SFIIC : Annual Seminar in Marrakech

During this seminar, Imactiv-3D presented 3D illustrations of skin structures ranging from adipocytes to reconstructed skin or bioimpression models.

During this seminar, Imactiv-3D presented 3D illustrations of skin structures ranging from adipocytes to reconstructed skin or bioimpression models.
7 JUL 2017

Inexo : Symposium 2017 - Modèles Alternatifs

Imactiv-3D presented a complete 3D cell culture, imaging and quantification process for the evaluation of the cytotoxicity of compounds.in Montpellier

Imactiv-3D presented a complete 3D cell culture, imaging and quantification process for the evaluation of the cytotoxicity of compounds.in Montpellier
1 JAN 2019

IMALC start: Treatment of follicular lymphomas with anti-CD20 antibodies

Development of quantitative imaging tools for efficiency evaluation by light sheet microscopy. Project carried out by the ITAV imaging platform (CNRS USR3505) in the TRI - GENOTOUL area in collaboration with the CRCT team "Innovative strategies for anti-lymphoma therapy" (Inserm U1037) and the company IMACTIV-3D (Centre Pierre Potier). Funded by the Occitanie region (France)

Development of quantitative imaging tools for efficiency evaluation by light sheet microscopy. Project carried out by the ITAV imaging platform (CNRS USR3505) in the TRI - GENOTOUL area in collaboration with the CRCT team "Innovative strategies for anti-lymphoma therapy" (Inserm U1037) and the company IMACTIV-3D (Centre Pierre Potier). Funded by the Occitanie region (France)
13 NOV 2019

Establishment of the company

Hosting of the company within the CNRS in Toulouse (National Centre for Scientific Research).

Hosting of the company within the CNRS in Toulouse (National Centre for Scientific Research).